Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07310095 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)

StatusRecruiting
PhasePhase 4
Started2025-12-30
View on ClinicalTrials.gov ↗
The purpose of this study is to evaluate how well guselkumab works in participants with Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract) who no longer respond to treatment with ustekinumab.

Amendment record

Amended 6 times since 2025-12-16; most recent filed 2026-08-24. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2026-08-24
Amendment Study Identification, Study Status, Eligibility, IPDSharing v6
2026-07-02
Amendment Study Status v5
2026-06-04
Amendment Study Status v4
2026-05-07
Amendment Study Status v3
2026-04-09
Amendment Study Status, Contacts/Locations v2
2026-03-12
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
2025-12-16
Original filing
Trial Details
NCT Number NCT07310095
Lead Sponsor Xian-Janssen Pharmaceutical Ltd.
Conditions Crohn Disease
Enrollment 78 participants
Start Date 2025-12-30
Primary Completion 2027-09-15 (estimated)
Study Completion 2027-11-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-27